Gemcitabine and cisplatin in locally advanced and metastatic bladder cancer; 3- or 4-week schedule?

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Gemcitabine and cisplatin in locally advanced and metastatic bladder cancer; 3- or 4-week schedule? / Als, Anne Birgitte; Sengeløv, Lisa; Von Der Maase, Hans.

I: Acta Oncologica, Bind 47, Nr. 1, 2008, s. 110-119.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Als, AB, Sengeløv, L & Von Der Maase, H 2008, 'Gemcitabine and cisplatin in locally advanced and metastatic bladder cancer; 3- or 4-week schedule?', Acta Oncologica, bind 47, nr. 1, s. 110-119. https://doi.org/10.1080/02841860701499382

APA

Als, A. B., Sengeløv, L., & Von Der Maase, H. (2008). Gemcitabine and cisplatin in locally advanced and metastatic bladder cancer; 3- or 4-week schedule? Acta Oncologica, 47(1), 110-119. https://doi.org/10.1080/02841860701499382

Vancouver

Als AB, Sengeløv L, Von Der Maase H. Gemcitabine and cisplatin in locally advanced and metastatic bladder cancer; 3- or 4-week schedule? Acta Oncologica. 2008;47(1):110-119. https://doi.org/10.1080/02841860701499382

Author

Als, Anne Birgitte ; Sengeløv, Lisa ; Von Der Maase, Hans. / Gemcitabine and cisplatin in locally advanced and metastatic bladder cancer; 3- or 4-week schedule?. I: Acta Oncologica. 2008 ; Bind 47, Nr. 1. s. 110-119.

Bibtex

@article{a0fe67d005cf11deb05e000ea68e967b,
title = "Gemcitabine and cisplatin in locally advanced and metastatic bladder cancer; 3- or 4-week schedule?",
abstract = "BACKGROUND: Chemotherapy with gemcitabine and cisplatin (GC) is an active regimen in advanced transitional cell carcinoma (TCC). Traditionally, GC has been administered as a 4-week schedule. However, an alternative 3-week schedule may be more feasible. Long-term survival data for the alternative 3-week schedule and comparisons of the feasibility and toxicity between the two schedules have not previously been published. MATERIAL AND METHODS: We performed a retrospective analysis of patients with stage IV TCC, treated with GC by a standard 4-week or by an alternative 3-week schedule. RESULTS: A total of 212 patients received GC (3-week; n = 151, 4-week; n = 61). We found no statistical differences in overall survival between the two schedules (hazard ratio 1.15, 95{\%} CI 0.83-1.59), p = 0.40). Five-year survival rates were 14.9{\%} and 11.8{\%} for the 3- and 4-week schedule, respectively (p = 0.94). Response rates were 59.7{\%} and 55.6{\%}, respectively (p = 0.61). Toxicity was less pronounced in the 3-week schedule with regards to neutropenia, thrombocytopenia, and transfusion rates. Hematologic toxicity at day 15 in the 4-week schedule was common, leading to dose omissions in 47{\%} of cycles. Dose intensity for gemcitabine was accordingly lower in the 4 week-schedule. The higher dose intensity of cisplatin in the 3-week schedule, did not lead to increased renal toxicity. In 13 patients with impaired renal function, cisplatin was split into 2 days, which was feasible and efficient. CONCLUSION: Efficacy parameters for the GC 3-week schedule were comparable to those for the 4-week schedule, whereas toxicity was less pronounced. The 3-week schedule may be an effective and feasible alternative GC-schedule Udgivelsesdato: 2008",
author = "Als, {Anne Birgitte} and Lisa Sengel{\o}v and {Von Der Maase}, Hans",
note = "Keywords: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Prognosis; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms",
year = "2008",
doi = "10.1080/02841860701499382",
language = "English",
volume = "47",
pages = "110--119",
journal = "Acta Oncologica",
issn = "0284-186X",
publisher = "Taylor & Francis",
number = "1",

}

RIS

TY - JOUR

T1 - Gemcitabine and cisplatin in locally advanced and metastatic bladder cancer; 3- or 4-week schedule?

AU - Als, Anne Birgitte

AU - Sengeløv, Lisa

AU - Von Der Maase, Hans

N1 - Keywords: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Prognosis; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms

PY - 2008

Y1 - 2008

N2 - BACKGROUND: Chemotherapy with gemcitabine and cisplatin (GC) is an active regimen in advanced transitional cell carcinoma (TCC). Traditionally, GC has been administered as a 4-week schedule. However, an alternative 3-week schedule may be more feasible. Long-term survival data for the alternative 3-week schedule and comparisons of the feasibility and toxicity between the two schedules have not previously been published. MATERIAL AND METHODS: We performed a retrospective analysis of patients with stage IV TCC, treated with GC by a standard 4-week or by an alternative 3-week schedule. RESULTS: A total of 212 patients received GC (3-week; n = 151, 4-week; n = 61). We found no statistical differences in overall survival between the two schedules (hazard ratio 1.15, 95% CI 0.83-1.59), p = 0.40). Five-year survival rates were 14.9% and 11.8% for the 3- and 4-week schedule, respectively (p = 0.94). Response rates were 59.7% and 55.6%, respectively (p = 0.61). Toxicity was less pronounced in the 3-week schedule with regards to neutropenia, thrombocytopenia, and transfusion rates. Hematologic toxicity at day 15 in the 4-week schedule was common, leading to dose omissions in 47% of cycles. Dose intensity for gemcitabine was accordingly lower in the 4 week-schedule. The higher dose intensity of cisplatin in the 3-week schedule, did not lead to increased renal toxicity. In 13 patients with impaired renal function, cisplatin was split into 2 days, which was feasible and efficient. CONCLUSION: Efficacy parameters for the GC 3-week schedule were comparable to those for the 4-week schedule, whereas toxicity was less pronounced. The 3-week schedule may be an effective and feasible alternative GC-schedule Udgivelsesdato: 2008

AB - BACKGROUND: Chemotherapy with gemcitabine and cisplatin (GC) is an active regimen in advanced transitional cell carcinoma (TCC). Traditionally, GC has been administered as a 4-week schedule. However, an alternative 3-week schedule may be more feasible. Long-term survival data for the alternative 3-week schedule and comparisons of the feasibility and toxicity between the two schedules have not previously been published. MATERIAL AND METHODS: We performed a retrospective analysis of patients with stage IV TCC, treated with GC by a standard 4-week or by an alternative 3-week schedule. RESULTS: A total of 212 patients received GC (3-week; n = 151, 4-week; n = 61). We found no statistical differences in overall survival between the two schedules (hazard ratio 1.15, 95% CI 0.83-1.59), p = 0.40). Five-year survival rates were 14.9% and 11.8% for the 3- and 4-week schedule, respectively (p = 0.94). Response rates were 59.7% and 55.6%, respectively (p = 0.61). Toxicity was less pronounced in the 3-week schedule with regards to neutropenia, thrombocytopenia, and transfusion rates. Hematologic toxicity at day 15 in the 4-week schedule was common, leading to dose omissions in 47% of cycles. Dose intensity for gemcitabine was accordingly lower in the 4 week-schedule. The higher dose intensity of cisplatin in the 3-week schedule, did not lead to increased renal toxicity. In 13 patients with impaired renal function, cisplatin was split into 2 days, which was feasible and efficient. CONCLUSION: Efficacy parameters for the GC 3-week schedule were comparable to those for the 4-week schedule, whereas toxicity was less pronounced. The 3-week schedule may be an effective and feasible alternative GC-schedule Udgivelsesdato: 2008

U2 - 10.1080/02841860701499382

DO - 10.1080/02841860701499382

M3 - Journal article

VL - 47

SP - 110

EP - 119

JO - Acta Oncologica

T2 - Acta Oncologica

JF - Acta Oncologica

SN - 0284-186X

IS - 1

ER -

ID: 10926589